Neoadjuvant Crizotinib in Advanced Inflammatory Myofibroblastic Tumour with ALK Gene Rearrangement

Abstract

Background

Inflammatory myofibroblastic tumours (IMTs) are rare sarcomas that were first described in the lung. They are composed of myofibroblastic mesenchymal spindle cells accompanied by an inflammatory infiltrate of plasma cells. Complete resection is the treatment of choice. There is currently no standard treatment for inoperable or recurrent disease. Expression of ALK protein triggered by ALK gene rearrangement at chromosome 2p23 has been found in 36%-60% of IMTs.

Case report

We report a rapid early response to crizotinib as neoadjuvant therapy, enabling surgical excision of a large ALK(-translocated IMT, which resulted in complete disease clearance. To the best of our knowledge, this is the first case in the literature of a patient with IMT in whom crizotinib was used successfully in the neoadjuvant or curative setting.

Keywords

Crizotinib Inflammatory myofibroblastic tumour (IMT)

Get full access to this article

View all access options for this article.

References

Coffin

C.M.

Watterson

Priest

J.R.

Dehner

L.P.

Extrapulmonary inflammatory myofibroblastic tumor (inflammatory pseudotumor). A clinicopathologic and immunohistochemical study of 84 cases. Am J Surg Pathol. 1995; 19(8): 859–872.

Pungpapong

Geiger

X.J.

Raimondo

Inflammatory myofibroblastic tumor presenting as a pancreatic mass: a case report and review of the literature. JOP. 2004; 5(5): 360–367.

Santoro

Tursz

Mouridsen

Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. J Clin Oncol. 1995; 13(7): 1537–1545.

Edmonson

J.H.

Ryan

L.M.

Blum

R.H.

Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas. J Clin Oncol. 1993; 11(7): 1269–1275.

Gleason

B.C.

Hornick

J.L.

Inflammatory myofibroblastic tumours: where are we now?

J Clin Pathol. 2008; 61(4): 428–437.

Brunn

Two interesting benign lung tumors of contradictory histopathology. J Thorac Surg. 1939; 9: 119–131.

Coffin

C.M.

Humphrey

P.A.

Dehner

L.P.

Extrapulmonary inflammatory myofibroblastic tumor: a clinical and pathological survey. Semin Diagn Pathol. 1998; 15(2): 85–101.

Wenig

B.M.

Devaney

Bisceglia

Inflammatory myofibroblastic tumor of the larynx. A clinicopathologic study of eight cases simulating a malignant spindle cell neoplasm. Cancer. 1995; 76(11): 2217–2229.

Sciot

Dal Cin

Fletcher

C.D.

Inflammatory myofibroblastic tumor of bone: report of two cases with evidence of clonal chromosomal changes. Am J Surg Pathol. 1997; 21(10): 1166–1172.

10.

Ramachandra

Hollowood

Bisceglia

Fletcher

C.D.M.

Inflammatory pseudotumour of soft tissues: a clinicopathological and immunohistochemical analysis of 18 cases. Histopathology. 1995; 27(4): 313–323.

11.

Häusler

Schaade

Ramaekers

V.T.

Doenges

Heimann

Sellhaus

Inflammatory pseudotumors of the central nervous system: report of 3 cases and a literature review. Hum Pathol. 2003; 34(3): 253–262.

12.

Rabban

J.T.

Zaloudek

C.J.

Shekitka

K.M.

Tavassoli

F.A.

Inflammatory myofibroblastic tumor of the uterus: a clinicopathologic study of 6 cases emphasizing distinction from aggressive mesenchymal tumors. Am J Surg Pathol. 2005; 29(10): 1348–1355.

13.

Coffin

C.M.

Hornick

J.L.

Fletcher

C.D.

Inflammatory myofibroblastic tumor: comparison of clinicopathologic, histologic, and immunohistochemical features including ALK expression in atypical and aggressive cases. Am J Surg Pathol. 2007; 31(4): 509–520.

14.

Firat

Ozturk

Akalin

Coker

Inflammatory myofibroblastic tumour. Can J Surg. 2009; 52(3): E60–E61.

15.

Meis

J.M.

Enzinger

F.M.

Inflammatory fibrosarcoma of the mesentery and retroperitoneum. A tumor closely simulating inflammatory pseudotumor. Am J Surg Pathol. 1991; 15(12): 1146–1156.

16.

Germanidis

Xanthakis

Tsitouridis

Regression of inflammatory myofibroblastic tumor of the gastrointestinal tract under infliximab treatment. Dig Dis Sci. 2005; 50(2): 262–265.

17.

Yin

W.H.

Takeuchi

Guan

Huang

Y.H.

Chan

J.K.

Inflammatory myofibroblastic tumor with RANBP2 and ALK gene rearrangement: a report of two cases and literature review. Diagn Pathol. 2013; 8(1): 147.

18.

Coffin

C.M.

Patel

Perkins

Elenitoba-Johnson

K.S.

Perlman

Griffin

C.A.

ALK 1 and p80 expression and chromosomal rearrangements involving 2p23 in inflammatory myofibroblastic tumor. Mod Pathol. 2001; 14(6): 569–576.

19.

Medeiros

L.J.

Elenitoba-Johnson

K.S.

Anaplastic large cell lymphoma. Am J Clin Pathol. 2007; 127(5): 707–722.

20.

Cools

Wlodarska

Somers

Identification of novel fusion partners of ALK, the anaplastic lymphoma kinase, in anaplastic large-cell lymphoma and inflammatory myofibroblastic tumor. Genes Chromosomes Cancer. 2002; 34(4): 354–362.

21.

Bridge

J.A.

Kanamori

Fusion of the ALK gene to the clathrin heavy chain gene, CLTC, in inflammatory myofibroblastic tumor. Am J Pathol. 2001; 159(2): 411–415.

22.

Mariño-Enríquez

Wang

W.L.

Roy

Epithelioid inflammatory myofibroblastic sarcoma: an aggressive intra-abdominal variant of inflammatory myofibroblastic tumor with nuclear membrane or perinuclear ALK.

Am J Surg Pathol. 2011; 35(1): 135–144.

23.

Plesec

T.P.

Gastrointestinal mesenchymal neoplasms other than gastrointestinal stromal tumors: focusing on their molecular aspects. Pathol Res Int. 2011; 2011: 952569.

24.

Shaw

A.T.

Kim

D-W

Nakagawa

Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med. 2013; 368(25): 2385–2394.

25.

Karen

Gomes

Sugo

Ella

Barbaric

Draga

, and Trahair

Toby

“Rapid regression of life threatening ALK positive epithelioid inflammatory myofibroblastic sarcoma following single agent crizotinib therapy”. In Asia-Pacific Journal Of Clinical Onclogy, vol. 8, pp. 300–300. 111 River St, Hoboken 07030-5774, NJ USA: Wiley-Blackwell, 2012.

26.

Butrynski

J.E.

D'Adamo

D.R.

Hornick

J.L.

Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor. N Engl J Med. 2010; 363(18): 1727–1733.

27.

O'Connell

Applebaum

Treatment of pseudotumors with nonsteroidal antiinflammatory drugs. J Pediatr Surg. 2000; 35(11): 1635–1637.

28.

Chan

P.W.

Omar

K.Z.

Ramanujam

T.M.

Successful treatment of unresectable inflammatory pseudotumor of the lung with COX-2 inhibitor. Pediatr Pulmonol. 2003; 36(2): 167–169.

29.

Chavez

Hoffman

M.A.

Complete remission of ALK-negative plasma cell granuloma (inflammatory myofibroblastic tumor) of the lung induced by celecoxib: a case report and review of the literature. Oncol Lett. 2013; 5(5): 1672–1676.

30.

Lovly

C.M.

Gupta

Lipson

Inflammatory myofibroblastic tumors harbor multiple potentially actionable kinase fusions. Cancer Discov. 2014; 4(8): 889–895.

31.

Shaw

A.T.

Camidge

D.R.

Engelman

J.A.

Clinical activity of crizotinib in advanced non-small cell lung cancer (NSCLC) harboring ROSI gene rearrangement. J Clin Oncol. 2012; 30(Suppl): abstr 7508.

32.

Heigener

D.F.

Reck

Crizotinib. In: Martens

U.M.

, ed. Small Molecules in Oncology. Berlin, Heidelberg: Springer; 2014: 197–205.

33.

Sasaki

Okuda

Zheng

The neuroblastoma-associated F1174L ALK mutation causes resistance to an ALK kinase inhibitor in ALK-translocated cancers. Cancer Res. 2010; 70(24): 10038–10043.